Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Raynaud's syndrome in children: systematic review and development of recommendations for assessment and monitoring

CE. Pain, T. Constantin, N. Toplak, M. Moll, C. Iking-Konert, DP. Piotto, N. Aktay Ayaz, D. Nemcova, PH. Hoeger, M. Cutolo, V. Smith, I. Foeldvari, . ,

. 2016 ; 34 Suppl 100 (5) : 200-206. [pub] 20160727

Jazyk angličtina Země Itálie

Typ dokumentu časopisecké články, směrnice pro lékařskou praxi, přehledy

Perzistentní odkaz   https://www.medvik.cz/link/bmc17013478

OBJECTIVES: To develop recommendations for investigation and monitoring of children with Raynaud's syndrome, based on paediatric evidence collated by a systematic review. METHODS: A systematic review was undertaken to establish the paediatric evidence for assessment and monitoring of Raynaud's syndrome. An expert panel including members of the Paediatric Rheumatology European Society (PRES) Scleroderma Working Group, were invited to a consensus meeting where recommendations were developed based on evidence graded by the systematic review and where evidence was lacking, consensus opinion. A nominal technique was used where 75% consensus was taken as agreement. RESULTS: The expert panel recommended testing anti-nuclear antibody (ANA), more specific antibodies associated with connective tissue disease and nail-fold capillaroscopy in all children presenting with Raynaud's syndrome as data suggests these can be risk factors for evolution into a connective tissue disease. The frequency of follow-up recommended depends on presence of these risk factors with the aim to detect evolving connective tissue disease early in high risk individuals. Those with no abnormalities on capillaroscopy and negative autoantibodies were deemed low risk of progression, whereas those with ANA positivity, specific autoantibodies and/or nailfold capillary changes were deemed high risk and more frequent follow-up was recommended. CONCLUSIONS: Recommendations, primarily based on consensus opinion, were agreed regarding investigation and monitoring of children who present with Raynaud's syndrome. Further prospective studies are needed to better define the risk factors for progression to connective tissue disease.

000      
00000naa a2200000 a 4500
001      
bmc17013478
003      
CZ-PrNML
005      
20220428220733.0
007      
ta
008      
170413s2016 it f 000 0|eng||
009      
AR
035    __
$a (PubMed)27494080
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a it
100    1_
$a Pain, Clare E $u Alder Hey Children's NHS Foundation Trust, Liverpool, UK.
245    10
$a Raynaud's syndrome in children: systematic review and development of recommendations for assessment and monitoring / $c CE. Pain, T. Constantin, N. Toplak, M. Moll, C. Iking-Konert, DP. Piotto, N. Aktay Ayaz, D. Nemcova, PH. Hoeger, M. Cutolo, V. Smith, I. Foeldvari, . ,
520    9_
$a OBJECTIVES: To develop recommendations for investigation and monitoring of children with Raynaud's syndrome, based on paediatric evidence collated by a systematic review. METHODS: A systematic review was undertaken to establish the paediatric evidence for assessment and monitoring of Raynaud's syndrome. An expert panel including members of the Paediatric Rheumatology European Society (PRES) Scleroderma Working Group, were invited to a consensus meeting where recommendations were developed based on evidence graded by the systematic review and where evidence was lacking, consensus opinion. A nominal technique was used where 75% consensus was taken as agreement. RESULTS: The expert panel recommended testing anti-nuclear antibody (ANA), more specific antibodies associated with connective tissue disease and nail-fold capillaroscopy in all children presenting with Raynaud's syndrome as data suggests these can be risk factors for evolution into a connective tissue disease. The frequency of follow-up recommended depends on presence of these risk factors with the aim to detect evolving connective tissue disease early in high risk individuals. Those with no abnormalities on capillaroscopy and negative autoantibodies were deemed low risk of progression, whereas those with ANA positivity, specific autoantibodies and/or nailfold capillary changes were deemed high risk and more frequent follow-up was recommended. CONCLUSIONS: Recommendations, primarily based on consensus opinion, were agreed regarding investigation and monitoring of children who present with Raynaud's syndrome. Further prospective studies are needed to better define the risk factors for progression to connective tissue disease.
650    _2
$a mladiství $7 D000293
650    _2
$a věkové faktory $7 D000367
650    _2
$a antinukleární protilátky $x krev $7 D000974
650    _2
$a biologické markery $x krev $7 D015415
650    _2
$a dítě $7 D002648
650    _2
$a konsensus $7 D032921
650    _2
$a progrese nemoci $7 D018450
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a mikroskopická angioskopie $x normy $7 D020678
650    _2
$a pediatrie $x normy $7 D010372
650    _2
$a prediktivní hodnota testů $7 D011237
650    _2
$a prognóza $7 D011379
650    _2
$a Raynaudova nemoc $x krev $x diagnóza $x terapie $7 D011928
650    _2
$a revmatologie $x normy $7 D012219
650    _2
$a rizikové faktory $7 D012307
650    _2
$a sérologické testy $x normy $7 D012698
655    _2
$a časopisecké články $7 D016428
655    _2
$a směrnice pro lékařskou praxi $7 D017065
655    _2
$a přehledy $7 D016454
700    1_
$a Constantin, Tamás $u Semmelweis University, Budapest, Hungary.
700    1_
$a Toplak, Natasa $u University Children's Hospital Ljubljana, Slovenia.
700    1_
$a Moll, Monica $u University Children's Hospital, Tuebingen, Germany.
700    1_
$a Iking-Konert, Christof $u Universitätsklinikum Hamburg-Eppendorf, Germany.
700    1_
$a Piotto, Daniella P $u Universidade Federal de São Paulo, Brazil.
700    1_
$a Aktay Ayaz, Nuray $u Istanbul Kanuni Sultan Süleyman Education and Research Hospital, Turkey. $7 gn_A_00003100
700    1_
$a Nemcova, Dana $u Charles University, Prague, Czech Republic.
700    1_
$a Hoeger, Peter H $u Department of Paediatric Dermatology, Cath. Children's Hospital, Wilhelmstift, Hamburg, Germany.
700    1_
$a Cutolo, Maurizio $u University of Genoa, Italy.
700    1_
$a Smith, Vanessa $u Ghent University Hospital, Belgium.
700    1_
$a Foeldvari, Ivan $u Hamburger Zentrum für Kinder- und Jugendrheumatologie, Hamburg, Germany. foeldvari@t-online.de.
773    0_
$w MED00001116 $t Clinical and experimental rheumatology $x 0392-856X $g Roč. 34 Suppl 100, č. 5 (2016), s. 200-206
856    41
$u https://pubmed.ncbi.nlm.nih.gov/27494080 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20170413 $b ABA008
991    __
$a 20220428220727 $b ABA008
999    __
$a ok $b bmc $g 1199943 $s 974256
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2016 $b 34 Suppl 100 $c 5 $d 200-206 $e 20160727 $i 0392-856X $m Clinical and Experimental Rheumatology $n Clin Exp Rheumatol $x MED00001116
LZP    __
$a Pubmed-20170413

Najít záznam

Citační ukazatele

Možnosti archivace